Early critic of diabetes drug says don't panic
Patients should not haphazardly stop taking the controversial diabetes drug Avandia, even though it has been linked to heart risks, an early critic of the drug said on Sunday.
Johnson &amp; Johnson will delay by five months the release of a study comparing its Cypher heart device with Boston Scientific Corp.'s Taxus, the first large-scale comparison of the only two drug-coated stents on the market.